L’escissione chirurgica è il trattamento di scelta per i melanomi primari e la radioterapia è l’alternativa accettata per il sottogruppo di lesioni non suscettibili di intervento chirurgico. Con il recente aumento dell’incidenza del melanoma, soprattutto negli anziani, c’è un numero crescente di casi che non sono né suscettibili di chirurgia né radioterapia. In questo articolo, esaminiamo gli approcci farmacoterapeutici al melanoma microinvasivo (melanoma invasivo in fase di crescita radiale) che potrebbero essere considerati in tali circostanze. Non ci sono farmaci approvati per il trattamento del melanoma primario e non sono stati effettuati studi randomizzati controllati con 5 o più anni di follow-up. Gli studi limitati e le numerose serie di casi presenti in letteratura sul trattamento farmacologico del melanoma primario si sono concentrati sulle terapie topiche.
Di conseguenza, forniamo una revisione dei potenziali agenti farmacoterapeutici nel trattamento del melanoma microinvasivo estrapolando dalla letteratura limitata disponibile sull’uso di fluorouracile, acido azelaico, derivati dell’acido retinoico, interferone (IFN) -α, imiquimod e altri agenti per melanoma in situ, melanoma invasivo e metastasi di melanoma epidermotropico. La nostra revisione indica che il fluorouracile topico e la tretinoina non sono efficaci come agenti singoli. L’efficacia di acido azelaico, tazarotene, cidofovir e IFN-α intralesionale, interleuchina-2 e IFN-β non è definita. Imiquimod è l’agente più studiato e promettente; tuttavia, il dosaggio ottimale, il regime terapeutico e i tassi di sopravvivenza non sono noti. A fronte di una crescente domanda di trattamenti non chirurgici, sono necessari studi clinici formali per accertare il ruolo degli agenti farmacoterapeutici nel trattamento del melanoma microinvasivo.
Un rapporto sullo stato del tazarotene topico nella gestione dell’acne vulgaris.
Il tazarotene è un retinoide sintetico che, a seconda della concentrazione e del veicolo, è approvato dalla Food and Drug Administration statunitense per il trattamento topico dell’acne vulgaris (AV) e della psoriasi a placche. Il tazarotene è anche usato come trattamento aggiuntivo per specifiche manifestazioni cliniche di pelle cronicamente fotodanneggiata (rughe sottili del viso, ipopigmentazione e iperpigmentazione facciale chiazzata e lentiggini facciali benigne), insieme a una cura completa della pelle e fotoprotezione dalla luce solare. La formulazione in gel è stata rilasciata negli Stati Uniti nel 1997, con la formulazione in crema resa disponibile nel 2000. Sono disponibili molteplici studi a sostegno dell’uso efficace e sicuro del tazarotene topico per ciascuna delle sue indicazioni.
Questo articolo fornisce una panoramica della farmacologia del tazarotene applicato per via topica, discutendo in particolare informazioni aggiornate sull’efficacia, tollerabilità e sicurezza del tazarotene topico per AV, inclusi studi in monoterapia e terapia di combinazione. Il tazarotene topico 0,1% in entrambe le formulazioni è altamente efficace nel ridurre le lesioni dell’acne infiammatorie e non infiammatorie e può essere utilizzato in combinazione con altri agenti topici, comprese le formulazioni contenenti perossido di benzoile o dapsone 5% gel. Sebbene molti pazienti tollerino l’uso del tazarotene topico senza problemi o preoccupazioni significativi, alcuni pazienti manifestano reazioni di tollerabilità al sito di applicazione, che di solito possono essere gestite con un’adeguata cura della pelle e sono meno frequenti con la formulazione in crema.
Tazarotene topico per il trattamento dell’ectropion nell’ittiosi.
OBBIETTIVO
L’ectropion è una complicazione di alcuni sottotipi di ittiosi ed è spesso associata a sostanziali conseguenze mediche e cosmetiche. Al momento non esiste uno standard di cura per il trattamento dell’ectropion in questa popolazione. I retinoidi causano disesione e assottigliamento dello strato corneo, riducendo così l’ipercheratosi che probabilmente è alla base dell’ectropion nei pazienti con ittiosi. In quanto tali, i retinoidi forniscono un potenziale trattamento efficace per l’ectropion in questo gruppo di pazienti.
METODI
Descriviamo un paziente con ittiosi recessiva per il quale l’applicazione quotidiana di tazarotene topico ha prodotto un miglioramento rapido e persistente dell’ectropion bilaterale della palpebra inferiore senza effetti avversi.
Tissue factor pathway inhibitor 2 |
|||
AP79755 | SAB | 1mg | 2640 EUR |
Tissue Factor Pathway Inhibitor TFPI |
|||
MBS606041-01mg | MyBiosource | 0.1mg | 835 EUR |
Tissue Factor Pathway Inhibitor TFPI |
|||
MBS606041-5x01mg | MyBiosource | 5x0.1mg | 3610 EUR |
Tissue Factor Pathway Inhibitor (TFPI) |
|||
MBS6508350-01mg | MyBiosource | 0.1mg | 860 EUR |
Tissue Factor Pathway Inhibitor (TFPI) |
|||
MBS6508350-5x01mg | MyBiosource | 5x0.1mg | 3725 EUR |
Sheep anti-Human Tissue Factor Pathway Inhibitor |
|||
MBS135479-1mg | MyBiosource | 1mg | 315 EUR |
Sheep anti-Human Tissue Factor Pathway Inhibitor |
|||
MBS135479-5mg | MyBiosource | 5mg | 580 EUR |
Sheep anti-Human Tissue Factor Pathway Inhibitor |
|||
MBS135479-5x5mg | MyBiosource | 5x5mg | 2420 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx103325 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx103326 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx103328 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx103329 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx104947 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx129517 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx132084 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx132085 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx132086 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx116110 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx001368 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx174804 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx433382-200ul | Abbexa | 200 ul | 460.8 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx238634-100ug | Abbexa | 100 ug | 661.2 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
20-abx323593 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx116110-100g | Abbexa | 100 µg | Ask for price |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx116110-10g | Abbexa | 10 µg | 612.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx116110-200g | Abbexa | 200 µg | Ask for price |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx129517-100l | Abbexa | 100 µl | 262.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx129517-1ml | Abbexa | 1 ml | 687.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx129517-200l | Abbexa | 200 µl | 325 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx174804-25mg | Abbexa | 25 mg | Ask for price |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx174804-5mg | Abbexa | 5 mg | 775 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx238634-100l | Abbexa | 100 µl | Ask for price |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx238634-50l | Abbexa | 50 µl | 350 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx132084-100tests | Abbexa | 100 tests | 237.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx132085-01mg | Abbexa | 0.1 mg | 275 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx132086-01mg | Abbexa | 0.1 mg | 237.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx349963-96tests | Abbexa | 96 tests | 287.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx433382-100g | Abbexa | 100 µg | 387.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx323593-100g | Abbexa | 100 µg | 250 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx323593-50g | Abbexa | 50 µg | 187.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx001368-100l | Abbexa | 100 µl | 400 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx001368-20l | Abbexa | 20 µl | 175 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx001368-50l | Abbexa | 50 µl | 275 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx104947-100g | Abbexa | 100 µg | 475 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx104947-20g | Abbexa | 20 µg | 212.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx104947-50g | Abbexa | 50 µg | 250 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103325-100g | Abbexa | 100 µg | 475 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103325-20g | Abbexa | 20 µg | 212.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103325-50g | Abbexa | 50 µg | 250 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103326-100g | Abbexa | 100 µg | 475 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103326-20g | Abbexa | 20 µg | 212.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103326-50g | Abbexa | 50 µg | 250 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103328-100g | Abbexa | 100 µg | 725 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103328-20g | Abbexa | 20 µg | 262.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103328-50g | Abbexa | 50 µg | 337.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103329-100g | Abbexa | 100 µg | 725 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103329-20g | Abbexa | 20 µg | 262.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody |
|||
abx103329-50g | Abbexa | 50 µg | 337.5 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) |
|||
MBS6508351-01mg | MyBiosource | 0.1mg | 845 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) |
|||
MBS6508351-5x01mg | MyBiosource | 5x0.1mg | 3660 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) |
|||
MBS6508352-01mg | MyBiosource | 0.1mg | 875 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) |
|||
MBS6508352-5x01mg | MyBiosource | 5x0.1mg | 3785 EUR |
Tissue Factor Pathway Inhibitor 2 Protein |
|||
20-abx263563 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor Rabbit mAb |
|||
E2R27344 | EnoGene | 100ul | 255 EUR |
Description: Available in various conjugation types. |
|||
Tissue Factor Pathway Inhibitor Rabbit mAb |
|||
E2R27346 | EnoGene | 100ul | 255 EUR |
Description: Available in various conjugation types. |
|||
Human Tissue factor pathway inhibitor (TFPI) |
|||
1-CSB-EP023437HU | Cusabio |
|
|
Description: Recombinant Human Tissue factor pathway inhibitor(TFPI),partial expressed in E.coli |
|||
Tissue Factor Pathway Inhibitor 2 Protein |
|||
abx263563-10mg | Abbexa | 10 mg | 1600 EUR |
Tissue Factor Pathway Inhibitor 2 Protein |
|||
abx263563-1mg | Abbexa | 1 mg | 225 EUR |
Tissue Factor Pathway Inhibitor 2 Protein |
|||
abx263563-5mg | Abbexa | 5 mg | 325 EUR |
Horse TFPI (Tissue factor pathway inhibitor) |
|||
MBS766164-10x96StripWells | MyBiosource | 10x96-Strip-Wells | 3900 EUR |
Horse TFPI (Tissue factor pathway inhibitor) |
|||
MBS766164-48StripWells | MyBiosource | 48-Strip-Wells | 340 EUR |
Horse TFPI (Tissue factor pathway inhibitor) |
|||
MBS766164-5x96StripWells | MyBiosource | 5x96-Strip-Wells | 2045 EUR |
Horse TFPI (Tissue factor pathway inhibitor) |
|||
MBS766164-96StripWells | MyBiosource | 96-Strip-Wells | 455 EUR |
Rabbit Tissue factor pathway inhibitor (TFPI) |
|||
1-CSB-YP023437RB | Cusabio |
|
|
Description: Recombinant Rabbit Tissue factor pathway inhibitor(TFPI) expressed in Yeast |
|||
Active Tissue Factor Pathway Inhibitor (TFPI) |
|||
APA394Hu61 | Cloud-Clone | 10ug | 360 EUR |
Rabbit Tissue factor pathway inhibitor (TFPI) |
|||
1-CSB-EP023437RB | Cusabio |
|
|
Description: Recombinant Rabbit Tissue factor pathway inhibitor(TFPI) expressed in E.coli |
|||
Rabbit Tissue factor pathway inhibitor (TFPI) |
|||
1-CSB-BP023437RB | Cusabio |
|
|
Description: Recombinant Rabbit Tissue factor pathway inhibitor(TFPI) expressed in Baculovirus |
|||
Rabbit Tissue factor pathway inhibitor (TFPI) |
|||
1-CSB-MP023437RB | Cusabio |
|
|
Description: Recombinant Rabbit Tissue factor pathway inhibitor(TFPI) expressed in Mammalian cell |
|||
Tissue Factor Pathway Inhibitor (TFPI) Protein |
|||
20-abx261170 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Protein |
|||
abx261170-10g | Abbexa | 10 µg | 325 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Protein |
|||
abx261170-2g | Abbexa | 2 µg | 225 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
20-abx103659 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
20-abx103660 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
20-abx103661 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
20-abx103662 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx122715-100ug | Abbexa | 100 ug | 469.2 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
20-abx006327 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
20-abx210903 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
20-abx174805 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
20-abx322259 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
20-abx323594 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
20-abx320289 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
20-abx339482 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx210903-100l | Abbexa | 100 µl | 350 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx210903-50l | Abbexa | 50 µl | 250 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx174805-100g | Abbexa | 100 g | 750 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx174805-500g | Abbexa | 500 g | Ask for price |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx122715-100l | Abbexa | 100 µl | Ask for price |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx122715-20l | Abbexa | 20 µl | 337.5 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx122715-50l | Abbexa | 50 µl | Ask for price |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx339482-100g | Abbexa | 100 µg | Ask for price |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx339482-20g | Abbexa | 20 µg | 250 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx339482-50g | Abbexa | 50 µg | 350 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx323594-100g | Abbexa | 100 µg | 250 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx323594-50g | Abbexa | 50 µg | 187.5 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx320289-100l | Abbexa | 100 µl | 350 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx320289-50l | Abbexa | 50 µl | 237.5 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx344660-100l | Abbexa | 100 µl | 350 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx344660-50l | Abbexa | 50 µl | 250 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx375235-96tests | Abbexa | 96 tests | 337.5 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx322259-100g | Abbexa | 100 µg | 350 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx322259-50g | Abbexa | 50 µg | 237.5 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx006327-100g | Abbexa | 100 µg | 275 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx006327-10g | Abbexa | 10 µg | 175 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx006327-200g | Abbexa | 200 µg | 400 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103659-100g | Abbexa | 100 µg | 712.5 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103659-20g | Abbexa | 20 µg | 262.5 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103659-50g | Abbexa | 50 µg | 325 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103660-100g | Abbexa | 100 µg | 725 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103660-20g | Abbexa | 20 µg | 262.5 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103660-50g | Abbexa | 50 µg | 337.5 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103661-100g | Abbexa | 100 µg | 775 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103661-20g | Abbexa | 20 µg | 275 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103661-50g | Abbexa | 50 µg | 350 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103662-100g | Abbexa | 100 µg | 850 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103662-20g | Abbexa | 20 µg | 287.5 EUR |
Tissue Factor Pathway Inhibitor 2 (TFPI2) Antibody |
|||
abx103662-50g | Abbexa | 50 µg | 375 EUR |
Eukaryotic Tissue Factor Pathway Inhibitor (TFPI) |
|||
EPA394Hu61 | Cloud-Clone | 10ug | 200 EUR |
Eukaryotic Tissue Factor Pathway Inhibitor (TFPI) |
|||
RPU58805-100ug | Biomatik Corporation | 100ug | 672 EUR |
Eukaryotic Tissue Factor Pathway Inhibitor (TFPI) |
|||
RPU58805-1mg | Biomatik Corporation | 1mg | 3120 EUR |
Eukaryotic Tissue Factor Pathway Inhibitor (TFPI) |
|||
RPU58805-50ug | Biomatik Corporation | 50ug | 495 EUR |
Eukaryotic Tissue Factor Pathway Inhibitor (TFPI) |
|||
MBS2124279-001mg | MyBiosource | 0.01mg | 185 EUR |
Eukaryotic Tissue Factor Pathway Inhibitor (TFPI) |
|||
MBS2124279-005mg | MyBiosource | 0.05mg | 340 EUR |
Eukaryotic Tissue Factor Pathway Inhibitor (TFPI) |
|||
MBS2124279-01mg | MyBiosource | 0.1mg | 515 EUR |
Eukaryotic Tissue Factor Pathway Inhibitor (TFPI) |
|||
MBS2124279-02mg | MyBiosource | 0.2mg | 630 EUR |
Eukaryotic Tissue Factor Pathway Inhibitor (TFPI) |
|||
MBS2124279-05mg | MyBiosource | 0.5mg | 1205 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody (FITC) |
|||
20-abx274012 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody (FITC) |
|||
20-abx274146 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody Pair |
|||
20-abx370061 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody Pair |
|||
20-abx370161 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody Pair |
|||
20-abx370357 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody Pair |
|||
20-abx370374 | Abbexa |
|
|
Tissue Factor Pathway Inhibitor (TFPI) Antibody (FITC) |
|||
abx274012-25mg | Abbexa | 25 mg | 975 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody (FITC) |
|||
abx274012-5mg | Abbexa | 5 mg | 412.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody (FITC) |
|||
abx274146-05ml | Abbexa | 0.5 ml | 425 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody Pair |
|||
abx370061-100g | Abbexa | 100 µg | 1437.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody Pair |
|||
abx370161-100g | Abbexa | 100 µg | 1350 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody Pair |
|||
abx370357-100g | Abbexa | 100 µg | 887.5 EUR |
Tissue Factor Pathway Inhibitor (TFPI) Antibody Pair |
|||
abx370374-100g | Abbexa | 100 µg | 1437.5 EUR |
Rat Tissue Factor Pathway Inhibitor CLIA Kit |
|||
MBS8426981-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Recombinant Tissue Factor Pathway Inhibitor (TFPI) |
|||
RPU50613-100ug | Biomatik Corporation | 100ug | 431.2 EUR |
Recombinant Tissue Factor Pathway Inhibitor (TFPI) |
|||
RPU50613-1mg | Biomatik Corporation | 1mg | 1911 EUR |
Recombinant Tissue Factor Pathway Inhibitor (TFPI) |
|||
RPU50613-50ug | Biomatik Corporation | 50ug | 346.5 EUR |
Recombinant Tissue Factor Pathway Inhibitor (TFPI) |
|||
RPU44028-100ug | Biomatik Corporation | 100ug | 517 EUR |
CONCLUSIONI
Saranno necessari ulteriori studi per affrontare in modo più completo e sistematico la sicurezza e l’efficacia dei retinoidi topici per il trattamento dell’ectropion nei pazienti con ittiosi; tuttavia, questo caso illustra che il tazarotene topico e altri retinoidi forniscono una potenziale opzione di trattamento per l’ectropion in questa popolazione. Incoraggiamo i medici a esplorare le terapie mediche come alternative all’intervento chirurgico per il trattamento dell’ectropion nei pazienti con ittiosi.